| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Sutro Biopharma, Inc.$29.73
-0.26 (-0.87%)
D 37Pipeline Score Overvalued Biotech · Commercial
Market Cap
423.71 M
EPS
-16.45
P/E Ratio
-
Value Trade
11.16 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
14.52 M
R&D Expenses
36.55 M
Operating CF
-42.26 M
Total Assets
241.99 M
Total Liabilities
308.88 M
Equity
-66.89 M
D/E Ratio
12,345
-41.69 %
Week
-26.8 %
1 Month
32.01 %
3 Month
208.07 %
6 Month
-86.3 %
5 Year
-83.09 %
All Time
Cash Data
Cash Position
202.56 M
Monthly Burn
14.09 M
Runway
12.7 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
242.43 K
52 Week Range
6.74 - 43.85
% held by Insiders
13.79 %
% held by Institutions
76.57 %
Enterprise Value
463.89 M
Total Shares
16.58 M
Short %
6.45 %
Float Shares
15.00 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sutro Biopharma, Inc.
398Total events
3Upcoming
51Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 3
Event history 395
Jun 2026
◆Topline ReadoutSTRO-004Clinical Data
Initial safety, PK and early activity data from Phase 1 dose-escalation trial of STRO-004
advanced solid tumorssource ↗
May 2026
▼Equity OfferingCorporate
Underwritten offering of 7,868,383 shares at $13.98 per share, gross proceeds $110M
Apr 19, 2026
▲Oral PresentationSTRO-004Presentation
Oral presentation of STRO-004 preclinical data at AACR 2026
TF-expressing solid tumorssource ↗
Apr 19, 2026
▲Poster PresentationSTRO-006Presentation
Poster presentation of STRO-006 preclinical data at AACR 2026
solid tumorssource ↗
Apr 19, 2026
▲Poster PresentationSTRO-227Presentation
Poster presentation of STRO-227 preclinical data at AACR 2026
solid tumorssource ↗
Apr 19, 2026
▲Oral PresentationASP2998Presentation
Oral presentation of ASP2998 preclinical data at AACR 2026 by Astellas
TROP2-expressing tumorssource ↗
Apr 17, 2026
●Oral PresentationSTRO-004Presentation
Oral presentation on STRO-004 at AACR 2026
TF-expressing solid tumorssource ↗
Apr 17, 2026
●Oral PresentationASP2998Presentation
Oral presentation on ASP2998 at AACR 2026
TROP2-expressing tumorssource ↗
Q2 2026
◆Topline ReadoutSTRO-004Clinical Data
Initial clinical data expected mid-2026
TF-expressing solid tumorssource ↗
Drug Pipeline Intelligence
D37
Pipeline Score $200M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.5x
rNPV / MCap Top 51%
Micro Cap (rank 447 of 911)
Percentile RankSutro Biopharma, Inc. faces pipeline headwinds (37/100), with $887M risk-adjusted pipeline value, led by STRO-002 in Neoplasm Malignant (Phase 1), across $52B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STRO-002 Monoclonal antibody | Neoplasm Malignant | Phase 1 | NCT06238687 | 17% | $787M | RECRUITING | 132 | STALLED | C (42) | Dec 30, 2027 | ELEVATED_RISK | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
luveltamab tazevibulin Fast TrackOrphanRare Pediatric | late-stage ovarian cancer | Phase 1b | 2024-09-14 | 56%; 35%; 9.3 months; 44%; 29% | Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 Read More | |
luveltamab tazevibulin Fast TrackOrphanRare Pediatric | late-stage ovarian cancer | Phase 1b | 2024-09-14 | 56%; 35%; 9.3 months; 44%; 29% | Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 Read More | |
luveltamab tazevibulin Fast TrackOrphanRare Pediatric | late-stage ovarian cancer | Phase 1b | 2024-09-14 | 56%; 35%; 9.3 months; 44%; 29% | Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STRO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
STRO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
STROSutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights – On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-cla
Sutro Biopharma reported financial results for Q1 2026, highlighting progress in its clinical and preclinical pipeline. The company anticipates initial safety and pharmacokinetic data from the Phase 1 trial of STRO-004 by mid-2026. Further advancements include the STRO-006 and STRO-227 ADC candidates, with IND submissions planned for 2026. Sutro's collaboration with Astellas has led to the first dual-payload iADC entering the clinic, reinforcing the company's commitment to developing innovative cancer therapies.
Read more →STROAACR Annual Meeting 2026 – Presentation and Posters
At the AACR Annual Meeting 2026, Sutro Biopharma presented several promising findings related to their investigational therapies. Notably, STRO-004 demonstrated superior efficacy in treating TF-expressing solid tumors. Additionally, a Phase 1 study highlighted its safety and preliminary anti-tumor activity. Other presentations included advancements in dual-payload antibody-drug conjugates targeting various cancer mechanisms.
Read more →STRO▲ +9.6%on this newsshared move
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Sutro Biopharma presented promising preclinical data on its ADC pipeline at the AACR Annual Meeting 2026. Notably, STRO-004 exhibited significant antitumor activity in various solid tumor models, outperforming benchmark ADCs. The company also highlighted its collaboration with Astellas on the TROP2-targeted iADC program, showcasing the potential of dual-payload ADCs in cancer therapy.
Read more →STRO▲ +10.5%on this news
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Sutro Biopharma reported its financial results for 2025, highlighting significant advancements in its clinical trials and pipeline. The company has completed dosing for three cohorts in the Phase 1 trial of STRO-004, with initial data expected in mid-2026. Additionally, Sutro is accelerating its dual-payload program STRO-227 and has commenced patient dosing in collaboration with Astellas Pharma. Financially, Sutro maintains a strong position with $141.4 million in cash, extending its runway into 2028.
Read more →STRO16th Annual World ADC London Summit – Presentation
The 16th Annual World ADC London Summit featured a presentation by Dr. Hans-Peter Gerber, focusing on the efficacy and safety profiles of dual payload antibody-drug conjugates (ADCs). The presentation emphasized novel linker payloads designed to overcome resistance mechanisms in cancer treatment. This innovative approach showcases advancements in ADC technology.
Read more →STROSutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma, a clinical-stage oncology company, announced its participation in several upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference. The company is focused on developing next-generation antibody-drug conjugates to enhance cancer treatment. Webcasts of select events will be available on their website.
Read more →STROSutro Biopharma Announces Participation at the 16th World ADC London Summit
Sutro Biopharma, a clinical-stage oncology company, announced its participation in the 16th World ADC London Summit from February 23-26, 2026. The event will feature discussions on their innovative antibody-drug conjugate platform, which aims to enhance cancer treatment options. Following the summit, content from the plenary session will be available on Sutro's website.
Read more →STRO▲ +11.9%on this news
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
Sutro Biopharma has announced the pricing of an underwritten offering of 7,868,383 shares at $13.98 each, aiming to raise approximately $110 million. The offering is set to close on February 11, 2026, and will support various corporate purposes, including funding research and development of its antibody-drug conjugates. The offering has attracted participation from several notable investors.
Read more →STRO▲ +11.9%on this newsshared move
February 2026 NASDAQ: STRO Forward-Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions and on inform
Sutro Biopharma has released forward-looking statements outlining its development pipeline and anticipated financial performance. The company emphasizes its proprietary platform for enhanced antibody-drug conjugates (ADCs), targeting unmet needs in oncology. Several candidates are advancing toward investigational new drug (IND) submissions in 2026, backed by a solid financial runway until at least mid-2028. However, there are inherent risks related to regulatory decisions and market competition that may impact future outcomes.
Read more →STROSutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sutro Biopharma, a clinical-stage oncology company focused on novel antibody drug conjugates, announced that CEO Jane Chung will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. This presentation highlights Sutro's advancements in cancer treatment through their unique ADC platform. A live webcast of the event will be available, along with an archived replay post-event.
Read more →STROSutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Sutro Biopharma has successfully regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split. As of December 16, 2025, the company's stock price averaged over $1.00, allowing it to meet the necessary listing standards. This development is significant for Sutro as it continues to advance its innovative cancer therapies.
Read more →STROSutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sutro Biopharma announced the granting of stock options and restricted stock units to new non-executive employees as part of their employment agreement. This decision was made in accordance with Nasdaq Listing Rule 5635(c)(4) to induce the acceptance of roles within the company. The compensation plan highlights Sutro's commitment to expanding its workforce while pursuing innovative cancer therapies through its ADC platform.
Read more →STRO▲ +19.2%on this news
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
Sutro Biopharma has initiated dosing in the first cohort of its Phase 1 trial for STRO-004, targeting Tissue Factor-expressing solid tumors. The trial aims to evaluate safety and preliminary anti-tumor activity, with initial data expected in mid-2026. STRO-004 is designed to improve drug exposure and reduce side effects compared to existing therapies.
Read more →STRO▼ -12.8%on this newsshared move
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
Sutro Biopharma has announced a 1-for-10 reverse stock split effective December 3, 2025, to comply with Nasdaq's minimum bid price requirement. This decision was approved by stockholders during the 2025 annual meeting. The split will reduce the number of outstanding shares while maintaining stockholder ownership percentages, and adjustments will be made to equity awards accordingly.
Read more →STROSociety for Immunotherapy of Cancer (SITC) 2025 Annual Meeting – Poster Presentation
The Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting will feature a presentation on next-generation immunostimulatory antibody-drug conjugates (iADCs). These iADCs aim to combine tumor cell killing with immune activation, potentially leading to durable antitumor immunity. The presentation can be accessed through a provided link.
Read more →STRO16th Annual World ADC San Diego – Presentations
The 16th Annual World ADC Conference in San Diego featured several presentations on advancements in antibody-drug conjugates (ADCs). Notable topics included the development of high-DAR dual-payload ADCs, immunostimulatory ADCs, and strategies to enhance therapeutic indices. Researchers presented their findings on overcoming resistance mechanisms and improving supply chain efficiencies in ADC manufacturing.
Read more →STROSutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
Sutro Biopharma hosted a virtual R&D Day to showcase its innovative ADC pipeline, including the initiation of a Phase 1 study for STRO-004, a Tissue Factor ADC. The company also introduced STRO-227, its first dual-payload candidate targeting PTK7. Sutro aims to address difficult-to-treat solid tumors and improve cancer care through its unique platform technology.
Read more →STROSutro R&D Day – Presentation
Sutro Biopharma held a Research and Development Day, presenting key updates on their pipeline and future projects. The event included a webcast for broader engagement with stakeholders. The company aims to enhance transparency and communication regarding their innovative therapies. A presentation deck is available for further details.
Read more →STRO▼ -13.4%on this newsshared move
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma announced positive developments in its third quarter 2025 report, including FDA clearance for its STRO-004 ADC, which is set to enter clinical trials by year-end. The company highlighted advancements in its dual-payload ADC programs and a strong cash position that extends its runway into mid-2027. Despite restructuring costs and modest revenue growth, Sutro remains optimistic about its pipeline and strategic focus.
Read more →STROSutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
Sutro Biopharma, Inc. has announced a virtual Research & Development Day scheduled for November 12, 2025. The event will focus on the company's innovative platform and its next-generation antibody-drug conjugate (ADC) pipeline. Attendees can access the live webcast starting at 7:00 AM PT. Sutro aims to enhance cancer treatment through advanced ADC technologies.
Read more →STROSutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
Sutro Biopharma will host a virtual Research & Development Day on November 12, 2025, to present its platform innovations and next-generation antibody-drug conjugate pipeline. The event will be accessible via a live webcast starting at 7:00 AM PT. An archived version will be available post-event.
Read more →STROSutro Biopharma Announces Participation at the 16th Annual World ADC Conference
Sutro Biopharma announced its participation in the 16th Annual World ADC Conference in San Diego, where it will present new preclinical data on its innovative antibody drug conjugates (ADCs). The company aims to showcase advancements in dual-payload ADCs that could redefine treatment paradigms in oncology. Sutro's commitment to innovation is underscored by its unique cell-free platform designed to improve drug exposure and reduce side effects.
Read more →STROWhitepaper: The Power of Partnership in Advancing Innovation
Sutro Biopharma has partnered with Boehringer Ingelheim to enhance their cell-free technology platform for producing antibody-drug conjugates (ADCs). This collaboration aims to scale up production capabilities, which could lead to significant advancements in cancer therapy. The whitepaper discusses the implications of this innovative approach in the biopharma industry.
Read more →STROSutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
Sutro Biopharma announced an operational restructuring aimed at extending its cash runway into at least mid-2027. This decision is driven by the need to prioritize the advancement of its antibody-drug conjugate (ADC) programs. The restructuring will involve a significant workforce reduction, but it is expected to strengthen the company's financial position as it approaches key clinical milestones.
Read more →STROSutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma reported its financial results for Q2 2025, highlighting a revenue increase to $63.7 million, driven by collaborations. The company is preparing to initiate a first-in-human study for STRO-004 and has expanded its preclinical data across its pipeline. However, restructuring costs and a net loss of $11.5 million were noted, alongside the decision by Ipsen not to advance the STRO-003 program.
Read more →STROSutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights – On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 –
Sutro Biopharma reported its second quarter 2025 financial results, highlighting significant advancements in its pipeline, including plans to initiate a first-in-human study with STRO-004, a potential best-in-class Tissue Factor ADC, by the second half of 2025. The company has generated encouraging preclinical data and announced a research collaboration with the FDA to enhance regulatory standards for antibody drug conjugates. Despite strong cash reserves allowing operations into early 2027, the company faced challenges including the decision from Ipsen not to proceed with STRO-003.
Read more →STRO▲ +7.1%on this news
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates
Sutro Biopharma has announced a collaboration with the FDA to enhance regulatory standards for antibody drug conjugates (ADCs). This partnership will leverage Sutro's innovative cell-free XpressCF technology and the FDA's analytical capabilities to develop reference materials. The collaboration aims to improve ADC quality assessments and is expected to have a significant impact on the industry.
Read more →STROSutro Biopharma Appoints Greg Chow as Chief Financial Officer
Sutro Biopharma has appointed Greg Chow as Chief Financial Officer, effective June 2, 2025. Chow brings over 25 years of experience in corporate finance and drug development. His leadership is expected to strengthen Sutro's financial position as it advances its pipeline of antibody drug conjugates. The company also granted Chow stock options and restricted shares as part of his compensation.
Read more →STRO21st Annual PEGS Boston Summit – Presentation
Sutro Biopharma presented at the 21st Annual PEGS Boston Summit, highlighting its contributions to the biopharma industry. The presentation is part of a broader engagement strategy to connect with industry leaders and showcase innovative developments. Attendees can access the presentation through a provided link.
Read more →STROSutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma reported its first quarter 2025 financial results, highlighting a strategic shift towards its next-generation ADC portfolio. The company anticipates three INDs in the next three years, with promising preclinical results for STRO-004 and STRO-006. However, it also faced a significant net loss and is undergoing a major restructuring, including workforce reductions.
Read more →STROThe Citizens Life Sciences Conference – Presentation
The Citizens Life Sciences Conference featured a presentation by Sutro Biopharma, showcasing their latest advancements in the life sciences sector. The presentation emphasized innovative research and development initiatives aimed at improving patient outcomes. Stakeholders and investors were engaged through detailed insights into the company's strategic direction and future plans.
Read more →STROSutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights - Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - -
Sutro Biopharma reported its financial results for Q1 2025, highlighting a strategic pivot towards its next-generation ADC portfolio. The company has prioritized STRO-004, supported by positive preclinical data. Sutro anticipates filing three INDs over the next three years, reflecting confidence in its pipeline despite a planned reduction in workforce and the closure of its manufacturing facility. The company's cash position remains strong, with $249 million ensuring operational stability into early 2027.
Read more →STRO2025 American Association for Cancer Research (AACR) Annual Meeting – Poster Presentations
The 2025 American Association for Cancer Research (AACR) Annual Meeting will feature several poster presentations by Sutro Biopharma. Notable topics include the preclinical activity of STRO-004, an antibody-drug conjugate (ADC) targeting tissue factor, and advancements in dual-payload ADCs combining Topo1i with inhibitors. These presentations highlight Sutro's commitment to innovative cancer therapies.
Read more →STROSutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
Sutro Biopharma announced plans to present its innovative ADC programs, including the novel STRO-004, at the AACR Annual Meeting in 2025. The presentations will highlight substantial preclinical data showcasing the drug's potent anti-tumor effects and safety profile. Additionally, Sutro will demonstrate the capabilities of its XpressCF+ platform, which allows for the efficient production of advanced dual-payload ADCs. The company is optimistic about the upcoming first-in-human trial for STRO-004 set to begin later this year.
Read more →STRO▲ +15.1%on this news
Society Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer – Presentation
The Society of Gynecologic Oncology (SGO) Annual Meeting showcased a presentation on advancements in women's cancer treatment. This event provided a platform for sharing innovative research and fostering collaboration within the gynecologic oncology community. The presentation is accessible through a provided link, emphasizing the importance of ongoing education and awareness in this field.
Read more →STRO▲ +15.1%on this newsshared move
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Sutro Biopharma presented encouraging data from the REFRαME-O1 trial at SGO 2025, showing that luveltamab tazevibulin (luvelta) achieved a 32% overall response rate in patients with platinum-resistant ovarian cancer. The optimized dose demonstrated consistent safety and efficacy across various Folate Receptor-α expression levels. Despite these promising results, Sutro announced plans to deprioritize further investment in luvelta's development.
Read more →STRO▼ -6.7%on this news· ran to -40% by day 1shared move
Sutro Biopharma, Inc. Conference Call – Presentation
Sutro Biopharma, Inc. held a conference call where they presented updates on their operations and future plans. The event aimed to engage stakeholders and provide insights into the company's progress. Interested parties can access the presentation and webcast through provided links, enhancing transparency and communication.
Read more →STRO▼ -6.7%on this news· ran to -40% by day 1shared move
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
Sutro Biopharma has completed a strategic portfolio review, prioritizing its next-generation ADC pipeline, particularly the exatecan ADC STRO-004, expected to enter clinical trials in late 2025. The company will deprioritize investment in luvelta development and reduce its workforce by almost 50 percent as part of this restructuring. Jane Chung, the current President and COO, will take over as CEO from Bill Newell. Despite these changes, Sutro maintains a strong financial position with a cash runway expected into Q4 2026 without anticipated milestones from collaborations.
Read more →STRO▼ -6.7%on this news· ran to -40% by day 1shared move
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
Sutro Biopharma reported its full-year financial results for 2024, revealing a notable decline in revenue from $153.7 million in the previous year to $62.0 million. The company has indicated a cash balance of $316.9 million, which it expects to last into at least Q4 2026, despite incurring total operating expenses of $300.5 million. A strategic review of its portfolio has commenced, focusing on next-generation antibody drug conjugates, which may impact future development priorities. Management has also undergone changes as part of this transition process.
Read more →STRO▼ -6.7%on this news· ran to -40% by day 1shared move
Sutro Biopharma, Inc. Selected Statements of Operations Financial Data (Unaudited) (In thousands, except share and per share amounts) For the year ended December 31 2024 2023 2022 Revenues $ 62,043 $ 153,731 $ 67,772 Ope
Sutro Biopharma, Inc. reported its full year 2024 financial results, revealing a significant decrease in revenue, down to $62.0 million compared to $153.7 million in 2023. The company undertook a strategic portfolio review, prioritizing its next-generation ADC programs, while also announcing key management changes associated with the transition. Despite a cash reserve of $316.9 million, Sutro faced increased operating expenses totaling $300.5 million, resulting in a net loss of $227.5 million. The company emphasizes a cash runway into at least Q4 2026, aiming to navigate its restructured financial strategy.
Read more →STRO15th Annual World ADC London 2025 – Presentation
Sutro Biopharma will present at the 15th Annual World ADC London 2025, highlighting their advancements in antibody-drug conjugate (ADC) technology. This event is significant for networking and showcasing innovative research in the biopharma sector. The presentation aims to attract attention from industry leaders and potential investors.
Read more →STRO▼ -9.7%on this newsshared move
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Sutro Biopharma, Inc. announced its upcoming presentation at the TD Cowen 45th Annual Health Care Conference scheduled for March 3-5, 2025, in Boston, MA. The presentation will be available for access via the company's Investor Relations section on its website. Sutro is recognized for its innovative approach to developing site-specific antibody drug conjugates, with several clinical-stage candidates in its pipeline, including a target ADC currently in registrational studies.
Read more →STRO43rd Annual J.P. Morgan Healthcare Conference – Presentation
Sutro Biopharma recently presented at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is available for viewing through a provided link, showcasing the company's latest developments and engagement in the biopharma sector. This event is a key opportunity for Sutro to connect with investors and industry peers.
Read more →STROSutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale
Sutro Biopharma and Boehringer Ingelheim BioXcellence have successfully collaborated to scale up the production of luveltamab tazevibulin (luvelta) using Sutro’s cell-free protein synthesis technology. This achievement marks a significant milestone as it allows commercial-scale manufacturing under Good Manufacturing Practice (GMP) conditions. The partnership aims to enhance the development of antibody-drug conjugates (ADCs) with improved safety and efficacy profiles for various cancers. Sutro is also seeking further partnerships to leverage this technology in its product pipeline.
Read more →STROSutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sutro Biopharma, a clinical-stage oncology company, announced that CEO Bill Newell will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation aims to highlight Sutro's innovative therapies and ongoing clinical studies, demonstrating the company's focus on developing novel antibody drug conjugates for cancer treatment. This event will be accessible online, allowing investors and stakeholders to follow Sutro’s advancements in the oncology sector. The company continues to build upon its promising pipeline and strategic partnerships.
Read more →STRO▼ -16.4%on this news
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
Sutro Biopharma announced the selected dose of 5.2 mg/kg for luvelta in the REFRαME-O1 trial, showing a 32% objective response rate in evaluable patients with platinum-resistant ovarian cancer. The trial confirmed luvelta's efficacy across various levels of folate receptor alpha expression. The company plans to apply for Accelerated Approval by mid-2027.
Read more →STROJefferies London Healthcare Conference – Presentation
Sutro Biopharma participated in the Jefferies London Healthcare Conference, showcasing their latest developments. The presentation is accessible online, allowing stakeholders and investors to gain insights into the company's progress and future plans. This event highlights Sutro's commitment to transparency and engagement with the healthcare community.
Read more →STROSutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Sutro Biopharma reported its financial results for Q3 2024, highlighting significant advancements in its clinical programs, including two new trials for luvelta. The company showcased promising data from a Phase 1b study, indicating a 56% response rate. Despite a decrease in revenue and increased operating expenses, Sutro maintains a strong cash position of $388.3 million, supporting its ongoing development efforts.
Read more →STROSutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - -
Sutro Biopharma has announced its financial results for Q3 2024, reporting a cash position of $388.3 million. The company is progressing with its lead program luvelta, initiating two new clinical trials while also presenting encouraging results from a Phase 1b study. Sutro expects to file three IND applications in the next three years, focusing on next-generation ADC technology. However, the company reported a decrease in revenue compared to the previous year and an increase in operating expenses.
Read more →STRO15th Annual World ADC Conference – Presentations
The 15th Annual World ADC Conference showcased several key presentations by Sutro Biopharma. Notable topics included the development of dual-payload antibody drug conjugates, clinical updates on Luvelta, and preclinical safety studies for STRO-004. Experts also discussed leveraging cell-free protein synthesis to enhance ADC therapeutic indices. The event highlighted significant advancements in the field of antibody-drug conjugates.
Read more →STROSutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Sutro Biopharma, Inc. announced its participation in the 15th Annual World ADC Conference, featuring five key presentations focused on advancements in antibody drug conjugates (ADCs). Key presentations include the development of dual-payload ADCs, updates on their ADC candidate targeting the folate receptor, and novel approaches to enhance therapeutic efficacy and safety. This reflects Sutro's commitment to innovation in cancer therapy and engagement with the scientific community.
Read more →STRO▲ +9.2%on this news· ran to +27% by day 3shared move
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Sutro Biopharma has initiated the REFRαME-P1 trial for luveltamab tazevibulin (luvelta), targeting pediatric patients with CBF/GLIS acute myeloid leukemia (AML). This registration-enabling study aims to evaluate the drug's efficacy and safety in a population with limited treatment options. Previous compassionate use data indicated meaningful clinical responses, including complete remission in some patients.
Read more →STROResearch Forum – Presentation
Sutro Bio has announced a research forum presentation, providing insights into its ongoing research efforts. The presentation materials are accessible online, allowing stakeholders to engage with the content. Additionally, a webcast is available for those interested in further details.
Read more →STROSutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Sutro Biopharma hosted a research forum to showcase its proprietary cell-free platform aimed at developing next-generation antibody drug conjugates (ADCs). The forum highlighted promising preclinical data for STRO-004, which showed improved anti-tumor efficacy and reduced toxicity compared to existing therapies. Furthermore, Sutro announced plans to submit three IND applications within three years, indicating a robust pipeline of innovative therapeutics aimed at addressing various tumor types. The presentation underscored Sutro's strategic focus on enhancing the therapeutic index of ADCs through novel design and formulation strategies.
Read more →STROSutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sutro Biopharma has announced the granting of 60,000 restricted stock units (RSUs) to a new employee as an inducement under Nasdaq Listing Rule 5635(c)(4). This action aims to support Sutro's recruitment efforts as it continues to develop its innovative cancer therapies. The RSUs will vest over a four-year period, contingent upon the employee's ongoing service with the company. Sutro Biopharma is based in South San Francisco and is dedicated to advancing its pipeline of antibody-drug conjugates.
Read more →STRO▼ -17.8%on this news
European Society for Medical Oncology (ESMO) Congress 2024 – Poster
Sutro Biopharma will present a poster at the European Society for Medical Oncology (ESMO) Congress 2024. This event provides a platform for sharing significant research findings with the oncology community. The poster presentation is expected to highlight important advancements in their research.
Read more →STRO▼ -17.8%on this newsshared move
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
Sutro Biopharma announced updated results from a Phase 1b study of luveltamab tazevibulin (luvelta) combined with bevacizumab for treating late-stage ovarian cancer at the ESMO Congress 2024. The study reported a 56% objective response rate at the recommended phase 2 dose, with ongoing expansion of the study that includes additional patient enrollment. Initial data from this expansion is expected in the first half of 2025, and no new safety concerns were observed with this treatment combination.
Read more →STROSutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
Sutro Biopharma, a clinical-stage oncology company, has announced it will host a Research Forum on October 10, 2024, to showcase its next-generation antibody drug conjugates (ADCs). The forum aims to provide insights into the company's pipeline, particularly in the field of cancer therapeutics. Attendees can access the live webcast via the company’s website, with an archived replay available post-event. Sutro continues to focus on innovative cancer treatments, benefitting patients with advanced therapeutics.
Read more →STROSutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
Sutro Biopharma has initiated the REFRαME-L1 Phase 2 trial for luveltamab tazevibulin (luvelta) in patients with non-small cell lung cancer (NSCLC) expressing Folate Receptor-α. The trial aims to evaluate the safety and efficacy of luvelta, with initial data expected in the first half of 2025. This development represents an important step in providing targeted therapies for advanced NSCLC.
Read more →STROSutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma reported its second quarter 2024 financial results, highlighting ongoing clinical trials and partnerships. The company is advancing its lead candidate, luvelta, with multiple studies underway, including a Phase 3 trial for ovarian cancer. Financially, Sutro holds $426 million in assets, but continues to experience significant operating losses.
Read more →STROSutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones - Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevaci
Sutro Biopharma reported its financial results for Q2 2024, highlighting substantial cash reserves and significant advancements in clinical trials. Key developments include ongoing studies of luvelta for various oncology indications with data presentations scheduled for ESMO 2024. Additionally, Sutro is initiating further registration-enabling trials and expanding its ADC pipeline. Despite these advancements, the company is facing increased operational expenses, which could present financial challenges moving forward.
Read more →STRO▲ +10.5%on this news· ran to +37% by day 3
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
Sutro Biopharma has appointed Dr. Barbara Leyman as Chief Business Development Officer, effective July 8, 2024. Dr. Leyman brings extensive experience in life sciences and a strong track record in deal-making. The company is currently advancing its lead candidate, luvelta, in two registration-directed trials for ovarian cancer and a rare pediatric cancer. This strategic hire is expected to bolster Sutro's business development efforts and enhance the company's innovative approach in the oncology space.
Read more →STROSutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma reported its Q1 2024 financial results, highlighting a strong cash position of $267.6 million and significant advancements in its clinical pipeline. The FDA has cleared an IND application for a Phase 2 trial of luvelta in non-small cell lung cancer, set to begin in the second half of 2024. Additionally, Sutro has entered a global licensing agreement with Ipsen for STRO-003, enhancing its financial prospects.
Read more →STROSutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones - Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S.
Sutro Biopharma has reported its financial results for the first quarter of 2024, highlighting several key advancements. The company received FDA clearance for an Investigational New Drug application for its treatment luvelta, aimed at non-small cell lung cancer. Sutro also reported a robust cash position bolstered by licensing agreements and an underwritten stock offering. Additionally, ongoing clinical trials are progressing, with upcoming milestones set for various therapeutic areas, including pediatric AML and ovarian cancer.
Read more →STROSutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
Sutro Biopharma has announced the initiation of Part 2 of the REFRαME-O1 trial, focusing on the efficacy of luvelta in patients with platinum-resistant ovarian cancer. The trial aims to enroll approximately 500 patients and includes a planned interim analysis for potential accelerated approval. The first part of the trial has successfully enrolled 50 patients, indicating strong demand for targeted therapies in this area.
Read more →STROBill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”
In a recent interview, Bill Newell, CEO of Sutro Biopharma, discussed the company's latest collaboration with Ipsen and its focus on developing therapies in the folate receptor alpha space. He emphasized the importance of non-cell protein synthesis in their innovative approach. The interview was conducted by Bard Loncar, founder of Biotech TV.
Read more →STROSutro Biopharma Announces Pricing of $75 Million Underwritten Offering
Sutro Biopharma has announced a $75 million underwritten offering of its common stock priced at $5.18 per share. The offering is set to involve approximately 14.5 million shares and is expected to close around April 4, 2024, pending customary conditions. Proceeds from the offering will primarily be used for general corporate purposes, including research and expansion efforts. The company emphasized that while they are optimistic about the venture, numerous factors could affect the success of their product candidates and market opportunities.
Read more →STROIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugat
Ipsen and Sutro Biopharma have entered an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate targeting solid tumors. Ipsen will lead the drug's development and commercialization, taking advantage of Sutro's advanced ADC technology. STRO-003 targets the ROR1 antigen and has demonstrated strong potential both in efficacy and safety in preclinical studies. The agreement includes potential milestone payments of up to $900 million, indicating significant investment in this treatment avenue.
Read more →STROIpsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors
Ipsen and Sutro Biopharma have entered an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate targeting the ROR1 tumor antigen. This agreement allows Ipsen to develop and commercialize STRO-003, which has demonstrated promising efficacy in preclinical studies. The collaboration aims to leverage Ipsen's expertise in oncology to bring this innovative treatment to patients.
Read more →STROSutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma announced its full-year financial results for 2023, highlighting significant developments in its oncology pipeline and management. The firm showcased data on its lead candidate, luveltamab tazevibulin (luvelta), particularly its efficacy in pediatric patients with relapsed AML. Financially, Sutro reported a cash position of $333.7 million, allowing for continued operations into 2025. However, the company also faces challenges, such as increased operating expenses and a competitive financing environment.
Read more →STROSutro Biopharma, Inc. Selected Statements of Operations Financial Data (Unaudited) (In thousands, except share and per share amounts) For the year ended December 31 2023 2022 2021 Revenues $ 153,731 $ 67,772 $ 61,880 Ope
Sutro Biopharma, Inc. reported strong financial results for the year ending 2023, highlighting a substantial increase in revenue to $153.7 million, driven by collaborations and licensing agreements. The company is advancing its lead drug, luveltamab tazevibulin, with ongoing clinical trials targeting various cancers, including pediatric acute myeloid leukemia, and it is positioned to support continued growth with a cash runway extending into mid-2025. Additionally, the leadership team was strengthened with the recent promotion of Jane Chung. Sutro is planning several investigational new drug applications and trials aimed at expanding its cancer treatment pipeline.
Read more →STRO▼ -12.1%on this news· ran to -22% by day 3
14th Annual World ADC London 2024 – Presentation
Sutro Biopharma is set to present at the 14th Annual World ADC London 2024. This event is significant in the field of antibody-drug conjugates, and the presentation will likely focus on the company's latest research and developments. The participation underscores Sutro's commitment to advancing ADC technology.
Read more →STROmAbs Journal – Production of Antibodies and Antibody Fragments Containing Non-Natural Amino acids in Escherichia Coli
The article discusses the production of antibodies and antibody fragments containing non-natural amino acids using Escherichia coli. This innovative approach could improve the efficacy of therapeutic antibodies. The research highlights potential advancements in antibody therapies, showcasing the importance of non-natural amino acids in enhancing therapeutic properties.
Read more →STROLuvelta Forum – Presentation
The Luvelta Forum presentation has been made available to the public, showcasing significant developments in the biopharma sector. This initiative aims to foster community engagement and provide insights into ongoing research and advancements. The presentation can be accessed through the provided link, enhancing transparency and information sharing.
Read more →STROSutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
Sutro Biopharma is showcasing the potential of luvelta, a FolRα-targeting ADC, in treating various cancers, particularly platinum-resistant ovarian cancer. The company highlights promising clinical data supporting luvelta's efficacy and safety. Sutro plans to advance two registration-directed trials in 2024 and has received Fast Track designation from the FDA for ovarian cancer.
Read more →STRO▲ +6.5%on this news· ran to -19% by day 3shared move
Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management's beliefs and assumptions and on information current
Sutro Biopharma recently presented forward-looking statements regarding its future financial performance and development activities. The company highlights the efficacy of its product candidate, Luveltamab tazevibulin, particularly in ovarian cancer patients, and its robust pipeline of oncology therapies. Sutro also emphasizes its strong financial position with substantial cash reserves capable of funding operations into late 2025. However, the company recognizes that its forward-looking statements involve uncertainties and potential risks that may affect actual outcomes.
Read more →STROSutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
Sutro Biopharma will host an investor webcast on January 4, 2024, to discuss the potential of Luveltamab tazevibulin, a FolRα-targeted ADC, in treating various cancers, particularly platinum-resistant ovarian cancer. The webcast will feature presentations from the management team and key opinion leaders, followed by a Q&A session. The company is actively enrolling patients in a Phase 2/3 study for this indication.
Read more →STRO65th American Society of Hematology Annual Meeting and Exposition – Poster
The 65th American Society of Hematology Annual Meeting featured a presentation by Dr. Soheil Meshinch on Luveltamab Tazevibulin (LT, STRO-002), an antibody-drug conjugate targeting the folate receptor alpha. This study highlights its anti-leukemic activity in patients with relapsed or refractory CBFA2T3::GLIS2 acute myeloid leukemia (AML). The findings suggest potential therapeutic benefits for this challenging patient population.
Read more →STROSutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
Sutro Biopharma announced positive data from the use of luveltamab tazevibulin (luvelta) in pediatric patients with relapsed/refractory CBF/GLIS acute myeloid leukemia (AML) at ASH 2023. The treatment demonstrated a complete remission rate of 42% in patients with significant disease and 75% in those with lower disease burden, showcasing the drug's potential efficacy. Luvelta also showed an acceptable safety profile, with minimal toxicity, allowing outpatient treatment for young patients in dire need of effective therapies.
Read more →STROSutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
Sutro Biopharma, a clinical-stage oncology company, will engage in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2023. CEO Bill Newell will represent the company, showcasing its focus on innovative cancer therapeutics. Sutro's technology aims to enhance patient outcomes through novel-format antibody drug conjugates. The company maintains a strong pipeline, including its lead candidate, luveltamab tazevibulin, indicating ongoing product innovation.
Read more →STROPiper Sandler 35th Annual Healthcare Conference – Presentation
Sutro Biopharma participated in the Piper Sandler 35th Annual Healthcare Conference, showcasing its latest developments and strategic initiatives. The presentation aimed to engage with investors and stakeholders, providing insights into the company's future direction. Attendees can access the presentation via a provided link.
Read more →STRO▼ -7.3%on this newsshared move
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
Vaxcyte has exercised an option to enter a manufacturing rights agreement with Sutro Biopharma, gaining control over the development of cell-free extract for its pneumococcal conjugate vaccine franchise. This move is part of Vaxcyte's strategy to support the commercialization of its vaccine candidates, particularly VAX-24, which is advancing into Phase 3 trials. The agreement includes a $50 million upfront payment and potential milestone payments totaling up to $60 million.
Read more →STROSutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
Sutro Biopharma has promoted Jane Chung to the newly established role of President and Chief Operating Officer, effective December 1, 2023. In her new position, Chung will focus on operational excellence and drive strategic growth for the company. The promotion reflects Sutro's ambition to strengthen its leadership in the antibody drug conjugate sector and enhance the company's overall business success. Chung has a background in oncology and extensive experience from her previous roles at AstraZeneca and other industry leaders.
Read more →STROSutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma reported its third quarter 2023 financial results, highlighting encouraging data for its drug Luvelta in treating endometrial cancer. The company has a cash position of $321.1 million, ensuring operations into 2025. Additionally, Sutro appointed Dr. Hans-Peter Gerber as Chief Scientific Officer, enhancing its leadership team. However, the company experienced a decline in revenue and an increase in operating expenses compared to the previous year.
Read more →STROSutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric p
Sutro Biopharma reported its Q3 2023 financial results, highlighting the promising data for its anti-cancer drug, luvelta, with specific activity noted in endometrial cancer. The company has a substantial cash reserve, allowing it to sustain operations into mid-2025. They announced the appointment of a new Chief Scientific Officer, Dr. Hans-Peter Gerber, further strengthening its leadership. Upcoming presentations at major conferences, including ASH 2023, are expected to showcase the efficacy of luvelta in treating acute myeloid leukemia in pediatric patients.
Read more →STRO▼ -7.5%on this news
ESMO Congress 2023 – Presentation
At the ESMO Congress 2023, Sutro Biopharma presented data on Luveltamab Tazevibulin (STRO-002), an antibody-drug conjugate targeting the folate receptor alpha. The results from the Phase 1 Dose Expansion study demonstrated clinical activity in patients with recurrent epithelial endometrial cancer, suggesting a potential new treatment option in this area.
Read more →STRO▼ -7.5%on this newsshared move
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
Sutro Biopharma presented promising preliminary data for luveltamab tazevibulin (luvelta) at the ESMO 2023 Congress. The Phase 1 dose-expansion study showed a 29% objective response rate in patients with recurrent endometrial cancer expressing high levels of FolRα. The drug exhibited a favorable safety profile consistent with earlier findings in other cancer types. These encouraging results underscore luvelta's potential to address unmet treatment needs in a challenging patient population.
Read more →STRO14th Annual World ADC Conference – Presentations and Poster
The 14th Annual World ADC Conference showcased several presentations on advancements in antibody-drug conjugates (ADCs). Key topics included the development of next-generation ADCs, novel linker payloads, and precision engineering for enhanced therapeutic indices. Presenters included notable figures such as Gang Yin and Alice Yam, who discussed their innovative research and findings.
Read more →STRO▼ -5.8%on this news· ran to -16% by day 3shared move
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
Sutro Biopharma, a clinical-stage oncology company, is exhibiting five presentations and one poster at the 14th Annual World ADC Conference in San Diego. The presentations will cover various innovative topics related to antibody drug conjugates (ADCs), including novel linker payloads and the development of next-generation treatments. Sutro's focus on improving therapeutic indices for patients and the introduction of site-specific dual conjugation techniques demonstrate its commitment to advancing cancer therapeutics. The event runs from October 16-19, 2023, with content to be published afterward on Sutro's website.
Read more →STROSutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
Sutro Biopharma announced the appointment of Dr. Hans-Peter Gerber as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber has over 25 years of experience in drug discovery and development, particularly in antibody drug conjugates (ADCs). His appointment is expected to enhance Sutro's efforts in developing next-generation cancer therapies. This move comes as the company aims to progress its promising pipeline of innovative treatments for cancer patients.
Read more →STROSutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma reported its financial results for Q2 2023, highlighting the initiation of the REFRaME study for luveltamab tazevibulin in platinum-resistant ovarian cancer. The company secured a $140 million upfront payment from Blackstone Life Sciences, enhancing its financial position. Despite a decrease in revenue and an increase in operating expenses, Sutro anticipates a cash runway into 2025 and plans to present further clinical data later this year.
Read more →STROSutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luve
Sutro Biopharma reported its financial results for Q2 2023, highlighting the initiation of the REFRaME-O1 trial for its drug luveltamab tazevibulin, targeting platinum-resistant ovarian cancer. The company recently entered into a royalty monetization agreement with Blackstone Life Sciences, improving its cash position significantly. Sutro is also set to present additional data from its ongoing studies involving luvelta at upcoming conferences. Overall, the company remains optimistic about its pipeline and future milestones.
Read more →STROSutro Biopharma and Blackstone Announce Royalty Financing Collaboration
Sutro Biopharma has entered a royalty financing collaboration with Blackstone Life Sciences, gaining an upfront payment of $140 million and eligibility for up to $250 million in milestone payments. This partnership allows Sutro to access non-dilutive growth capital to further advance its pipeline, particularly in developing therapies such as luveltamab tazevibulin for ovarian cancer. The collaboration emphasizes the innovative potential of Sutro’s technology platform, which supports Vaxcyte’s upcoming pneumococcal vaccine, VAX-24.
Read more →STRO▲ +5.7%on this news
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
Sutro Biopharma, Inc. has shared promising results from a Phase 1 dose-expansion study of luveltamab tazevibulin (luvelta) in patients with advanced ovarian cancer at the ASCO 2023 Annual Meeting. The results indicate substantial clinical benefits for FolRα-selected patients, establishing an objective response rate of 37.5%. This is coupled with the initiation of the Phase 2/3 pivotal study REFRaME-O1, which aims to explore further efficacy for patients with platinum-resistant ovarian cancer. The company remains optimistic about luvelta's potential across various indications targeting FolRα.
Read more →STROSutro Biopharma to Participate in the Jefferies Healthcare Conference
Sutro Biopharma announced that CEO Bill Newell will participate in a fireside chat at the Jefferies Healthcare Conference on June 7, 2023. This event showcases the company's commitment to engaging with investors and stakeholders. Sutro is focused on innovative antibody drug conjugates (ADCs) for various cancers and collaborates with major pharmaceutical companies. Additionally, the company has ongoing clinical studies for several of its product candidates.
Read more →STROSutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with a
Sutro Biopharma has reported its financial results for Q1 2023, highlighting advancements in its pipeline, including data presentation plans for the cancer treatment luveltamab tazevibulin at ASCO 2023. The company has a robust cash runway into the second half of 2024 and aims to initiate the Phase 2/3 REFRaME trial for luvelta soon. Recent positive findings regarding STRO-003's anti-tumor efficacy were also noted, contributing to optimistic projections for ongoing studies.
Read more →STROSutro Biopharma to Present at the JMP Securities Life Sciences Conference
Sutro Biopharma, a clinical-stage oncology company, announced that CEO Bill Newell will present at the JMP Securities Life Sciences Conference on May 15, 2023. The company's innovative work in antibody drug conjugates is highlighted, along with ongoing clinical studies for multiple cancer treatments. Sutro also collaborates with major pharmaceutical companies on additional cancer therapies, indicating a strong pipeline and partnerships.
Read more →STROSutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer
Sutro Biopharma announced that Trevor Hallam, Ph.D., will leave his position as President of Research & Chief Scientific Officer, effective May 31, 2023. Hallam will continue to contribute to the company as a member of its Scientific Advisory Board. Nicki Vasquez, Ph.D., will take on interim leadership of the research organization during this transition. The announcement highlights Sutro's ongoing focus on innovative therapies such as its antibody drug conjugates (ADCs) in various clinical studies.
Read more →STROSutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023
Sutro Biopharma presented expanded preclinical data for its antibody-drug conjugate STRO-003, which targets ROR1 and demonstrates strong anti-tumor activity and immune modulation. The findings suggest that STRO-003 could enhance the efficacy of checkpoint blockade therapy, especially for cancers with low ROR1 expression. Sutro is preparing for IND-enabling studies expected to finish by Q1 2024. The data was shared at the AACR Annual Meeting held in Orlando, Florida.
Read more →STRO▼ -6.1%on this news
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones - Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resi
Sutro Biopharma reported its financial results for 2022, highlighting significant achievements, including the upcoming Phase 2/3 study of luvelta for platinum-resistant ovarian cancer scheduled for Q2 2023. The company's financial position remains strong, with over $302 million in cash and investments. Additionally, clinical data from a Phase 1 study indicated meaningful benefits for patients treated with luvelta. Sutro continues to expand its collaborations and strengthen its pipeline with innovative therapies for various cancers.
Read more →STROSutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
Sutro Biopharma, a clinical-stage oncology company, announced that its CEO Bill Newell will participate in a panel discussion on Ovarian Cancer at the Cowen 43rd Annual Health Care Conference. The event is scheduled for March 8, 2023, in Boston, MA, and will be accessible online via Sutro's website. Sutro is known for its pioneering work in site-specific and novel-format antibody drug conjugates, with several candidates in clinical studies targeting various cancers.
Read more →STROSutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
Sutro Biopharma has appointed Dr. Anne Borgman as its new Chief Medical Officer, effective February 28, 2023. Dr. Borgman, who has over 20 years of experience in oncology and hematology, is expected to contribute to the upcoming Phase 2/3 study of luvelta for advanced ovarian cancer. Her previous roles include significant positions at Jazz Pharmaceuticals and Exelixis, where she led drug development efforts. The company is optimistic about leveraging her expertise to enhance its clinical pipeline and expand partnerships in the biopharma space.
Read more →STROSutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Sutro Biopharma has reported promising results from its Phase 1 dose-expansion study of STRO-002 (luvelta), showing an overall response rate of 43.8% in FolRα-selected ovarian cancer patients. The study indicated that these patients could experience a median duration of response of 5.4 months and a median progression-free survival of 6.6 months. Sutro also plans to initiate a Phase 2/3 registrational study named REFRaME in the near future. The overall safety profile remained consistent with previous data, and no new safety concerns were noted.
Read more →STROSutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
Sutro Biopharma, a clinical-stage oncology company, announced that CEO Bill Newell will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023. The presentation will highlight Sutro's advancements in antibody drug conjugates (ADCs) aimed at treating various cancers. The event can be accessed on Sutro's website, with an archived replay available for 30 days post-presentation. Sutro is collaborating with notable pharmaceutical companies and has several candidates in clinical trials.
Read more →STROSutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specif
Read more →STRO▼ -9.5%on this newsshared move
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
- New Agreement Provides Vaxcyte Access to Expanded Rights to Develop and Manufacture Cell-Free Extract, a Key Component of Vaxcyte's Vaccine Candidates - - Sutro to Receive $22.5 Million in Upfront Payments and is Eligible for Up to an Additional $135 Million Pending Option Exe
Read more →STROSutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
- A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete remission, of which seven patients were MRD negative - - Safety and efficacy profile in this patient population provides added confidence to advance clini
Read more →STRO▼ -5%on this news
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones - STRO-002 data demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones - STRO-002 data demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML are accepted for oral presentation at ASH 202
Read more →STROSutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that data from the Company’s co
Read more →STRO▲ +14.7%on this news
Sutro Biopharma Announces Departure of Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Chief Medical Officer, Art
Read more →STROSutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Execut
Read more →STRO▲ +7.5%on this news· ran to +18% by day 3
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones - Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfro
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones - Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfront payment of $90 million and $422.5 million in potential m
Read more →STROSutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executi
Read more →STROSutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has
Read more →STROSutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will host a
Read more →STRO▲ +20.8%on this news
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management's beliefs and assumptions and on information current
Company Overview June 2022 Sutro Biopharma NASDAQ: STRO Exhibit 99.1 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently ava
Read more →STRO▼ -12.1%on this news
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones - Cash, cash equivalents and marketable securities totaled $192.1 million as of
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones - Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023 - - Meetings wit
Read more →STROSutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones - Promising STRO-002 initial data on Phase 1 dose-expansion cohort were reported in January 2022, providing i
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones - Promising STRO-002 initial data on Phase 1 dose-expansion cohort were reported in January 2022, providing initial insights on a go-forward dosing regimen and biomarke
Read more →STROrelease, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Investor Contact Annie J. Chang Sutro Biopharma (650) 801-572
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer - 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolR expression levels and both dose levels. - Dose
Read more →STROSutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights , and Anticipated 2021 Milestones - Patient enrollment has been completed for the STRO-002 Phase 1 ovarian cancer dose-expansion cohort, a
Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 - Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on
Read more →STROSutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones - - Additional follow-up data on STRO-002 from the Phase 1 dose-escalation cohort were presen
Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones SOUTH SAN FRANCISCO, Calif., August 9, 2021 - Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing comp
Read more →STROSutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021 Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free sur
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021 SOUTH SAN FRANCISCO, Calif., May 19, 2021 - Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused o
Read more →STROSutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones - Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; e
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones - Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is ongoing - Merck initi
Read more →STROSutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones - Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones - Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway into the second half of 2023 - Four antibody-drug
Read more →STROSutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62 nd American Society of Hematology Annual Meeting - STRO-001 was generally w
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting - STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular
Read more →STROSutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer - Responses observed in 32% (10/31) of evaluable patients treated at clinically active dose le
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer SOUTH SAN FRANCISCO, Calif., Dec. 3, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufact
Read more →STROSutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments - KOL Discussion of STRO-002 Data Event scheduled for December 3 rd - Interim Phase 1 data from STRO-001 for
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments - KOL Discussion of STRO-002 Data Event scheduled for December 3rd - Interim Phase 1 data from STRO-001 for patients with NHL will be presented at ASH - Milestone pa
Read more →STROForward Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available t
Company Overview 2020 Wells Fargo Virtual Healthcare Conference NASDAQ: STRO Bill Newell, CEO Exhibit 99.1 Forward Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on our management's beliefs and assu
Read more →STROSutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments Encouraging STRO-002 Interim Phase 1 Clinical Data Presented at the AACR Virtual Meeting in April STRO-002 P
Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments Encouraging STRO-002 Interim Phase 1 Clinical Data Presented at the AACR Virtual Meeting in April STRO-002 Preclinical Data Presented at 2020 AACR Virtual Annual Mee
Read more →STROSutroVax Announces Name Change to Vaxcyte
FOSTER CITY, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and n
Read more →STROSutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments STRO-002 Encouraging Interim Phase 1 Clinical Data from an Ongoing Dose Escalation Study in Ovarian Cancer Pres
Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments STRO-002 Encouraging Interim Phase 1 Clinical Data from an Ongoing Dose Escalation Study in Ovarian Cancer Presented at the AACR Virtual Meeting STRO-001 Phase 1 Clinic
Read more →STROSutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer Summary of data for patients dosed at 2.9 mpk or higher in patients wi
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer - 62% of patients sa
Read more →STROSutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments STRO-002 Data from an Ongoing Phase 1 Clinical Trial in Ovarian and Endometrial Cancers Late-Breaking Abstract was
Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments STRO-002 Data from an Ongoing Phase 1 Clinical Trial in Ovarian and Endometrial Cancers Late-Breaking Abstract was accepted by AACR; Sutro plans to announce updated data in
Read more →STROSutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments STRO-002 Initial Safety Data from an Ongoing Phase 1 Trial in Ovarian and Endometrial Cancers presented at the
Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments STRO-002 Initial Safety Data from an Ongoing Phase 1 Trial in Ovarian and Endometrial Cancers presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics C
Read more →STROSutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer - Data is being presented as a poster today at AACR-NC
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 - Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discover
Read more →STROSutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments STRO-001 Initial Safety Data from an Ongoing Phase 1 Trial in Myeloma and Lymphoma presented at the European H
Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments STRO-001 Initial Safety Data from an Ongoing Phase 1 Trial in Myeloma and Lymphoma presented at the European Hematology Association ("EHA") Congress, June 15, 2019 STR
Read more →STROSummary and Conclusions (1) STRO-001 is the first ADC generated with novel cell-free protein synthesis technology and site-specific conjugation to be tested in the clinic. STRO-001 has been generally well tolerated. Most
Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies June 15, 2019 European Hematology Association Meeting Arturo Molina, MD, MS Chief Medical Officer Exhibit
Read more →STROSutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European
Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European Hematology Association ("EHA") Congress, June 15, 2019 S
Read more →STROSutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1
Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial Cance
Read more →STROSutro Biopharma Reports Third Quarter 2018 Financial Results - STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma - STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cance
Sutro Biopharma Reports Third Quarter 2018 Financial Results - STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma - STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN FRANCISCO, Calif., Nov. 14, 20
Read more →Competitive Position
How STRO ranks across every disease it competes inCompetitive Position is a premium feature
See how STRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial